Our study suggested that newly diagnosed monocyte‐like AML with high expression of CD4, CD14, CD64, and CD11b and low expression of CD117 had a poor response to frontline VEN/HMA treatment. This evidence concerns the gene ITGAM and acute myeloid leukemia.